STAT3 and dry eye syndrome: Moreover, although Visomitin’s safety profile has already been established in Phase III clinical trials for dry eye syndrome and no significant toxic effects were observed in our murine models, long-term studies are necessary to evaluate the potential off-target effects of STAT3 inhibition, considering the pleiotropic roles of STAT3 in immunity and hematopoiesis.